About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications

By: via Business Wire

Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Dorin Toader, Ph.D., as Head of Platform Technology. Dr. Toader brings more than 27 years of experience in drug discovery, including over 15 years in antibody-drug conjugates (ADCs). He will be responsible for defining and executing Orum’s technology vision, leading efforts across chemistry and antibody engineering, and guiding innovation in payload design, conjugation technologies, linker–payload strategies, structural biology, and computational modeling to advance Orum’s Dual-Precision Targeted Protein Degradation (TPD²) approach and expand its therapeutic applications.

“Dorin’s career reflects a proven ability to translate bold science into clinical candidates, including advancing multiple first-in-class ADC candidates into the clinic,” said Sung Joo (SJ) Lee, Founder and CEO of Orum. “His deep expertise in payload and linker design, together with Orum’s established capabilities in structure-based drug design and advanced computational methods such as physics-based modeling and machine learning, will strengthen our ability to innovate and scale our platforms. These combined strengths position us to build the next generation of targeted degrader-antibody conjugates with the potential to benefit patients across a broad range of cancers and other serious diseases.”

“The field of protein degradation is entering a transformative stage, and Orum is at the forefront with its proprietary Dual-Precision Targeted Protein Degradation approach,” said Dr. Toader. “I was drawn to Orum’s vision of creating entirely new classes of targeted degraders by uniting them with the precision of antibody delivery and its investment in structure-based design and computational innovation to drive DAC research and development. I look forward to applying my experience in payload and bioconjugation chemistry to expand Orum’s DAC platforms and broaden the impact of degrader-based medicines in the clinic.”

Dr. Toader joins Orum from Mersana Therapeutics, where he most recently served as Vice President of Chemistry and Bioconjugation, leading teams that delivered novel payload platforms and advanced pipeline programs, including the first STING agonist ADC candidate into clinical development. Earlier in his career, he held scientific and leadership roles at MedImmune, AstraZeneca, and Zeneca Pharmaceuticals, where he contributed to multiple first-in-class drug candidate nominations and investigational new drug (IND) applications. Over his 23-year career in oncology drug discovery, Dr. Toader has built and led high-performing cross-functional teams, authored more than 40 peer-reviewed publications, and is a named inventor on six granted patents.

About Orum’s TPD²® Approach

Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.

About Orum Therapeutics

Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea. For more info, visit www.orumrx.com.

Orum Therapeutics Forward-Looking Statements

This press release contains forward-looking statements that are based on the current expectations and beliefs of Orum Therapeutics, Inc. (“Orum”). Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the expansion and scaling of its platforms; the creation of next-generation targeted degrader-antibody conjugates; the potential initiation of clinical trials; and the range of indications for Orum’s products and their potential benefit to patients are forward-looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the uncertainty of success in research and development activities; competition from alternative therapies; and risks related to the recruitment and retention of key employees, fluctuating markets and economic conditions, and future fundraising. The forward-looking statements in this presentation speak only as of the date of this release, and Orum undertakes no obligation to update or revise any of the statements. Orum cautions investors not to place considerable reliance on the forward-looking statements contained in this release.

“The field of protein degradation is entering a transformative stage, and Orum is at the forefront with its proprietary Dual-Precision Targeted Protein Degradation approach,” said Dr. Toader.

Contacts

More News

View More
3 Utilities Plays You Can Lean on During Volatility
Via MarketBeat
Topics Economy Government World Trade
Tickers BIP DUK NEE XEL
Domino’s Delivers a Q3 Beat—and a Recipe for a Rebound
Via MarketBeat
Tickers DPZ
3 Small Caps Hitting 52-Week Highs: Take Profits or Let Ride?
Via MarketBeat
Topics Artificial Intelligence
Tickers ACMR RUN SONO
Fluence Energy Could Be a Multi-Bagger Play in Energy Technology
Via MarketBeat
Tickers FLNC GS
After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
Via MarketBeat
Tickers AEM B BAC GDX GDXJ GLD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.